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Abstract
Background Non-bullous pemphigoid (NBP) is a pemphigoid variant which frequently resembles other pruritic skin dis-
eases. In contrast with bullous pemphigoid (BP), blisters are absent. In BP, previous studies showed that IgE autoanti-
bodies may be involved in its pathogenesis. IgE-activated mast cells, basophils and eosinophils may participate in BP by
inducing pruritus and possibly blister formation, although the differential role of IgE in NBP compared with BP has not
yet been described.
Objective To assess IgE in serum and skin of NBP and BP patients.
Methods We examined total IgE and pemphigoid-specific IgE in the serum of 68 NBP and 50 BP patients by enzyme-
linked immunosorbent assay (ELISA). Sera of 25 pemphigus patients and 25 elderly patients with pruritus were included
as controls. Skin biopsies of 14 NBP and 14 BP patients with the highest IgE titres to NC16A were stained for IgE by
immunofluorescence techniques.
Results Total IgE was elevated in 63% of NBP and 60% of BP patients, and in 20% of pemphigus controls, as well as
60% of elderly controls. IgE ELISAs were more frequently positive in BP than in NBP (NC16A 18% vs. 9%, P = 0.139;
BP230 34% vs. 22%, P = 0.149). IgE ELISAs for NC16A and BP230 were positive in 8% and 20% of elderly controls,
respectively, while all pemphigus controls were negative. Two of 28 biopsies (7%; one NBP, one BP) showed linear IgE
along the basement membrane zone, while in most biopsies (71% NBP; 86% BP) IgE was bound to dermal cells.
Conclusion Since IgE was present in the serum and skin of both NBP and BP patients, this supports IgE-dependent
mechanisms common to both diseases, such as pruritus. However, it remains to be elucidated whether IgE contributes
to blister formation in BP.
Received: 11 May 2020; revised: 28 September 2020; Accepted: 2 October 2020
Introduction
Bullous pemphigoid (BP) is the most common autoimmune
bullous disease, mainly affecting elderly patients aged over 70.1,2
Most patients present with severe pruritus and skin blisters.1
However, one in five patients lacks blisters, a subtype termed
non-BP (NBP).3–5 While BP is well characterized and well stud-
ied, comparatively little is known about NBP.
The pathogenesis of BP involves IgG autoantibodies targeting
hemidesmosome proteins BP180 and BP230.6 BP230 (also BP
antigen 1) is a 230 kDa intracellular protein.7 BP180 (also BP
antigen 2, or type XVII collagen) is a transmembrane protein of
180 kDa.7 The extracellular non-collagenous 16A (NC16A)
domain of BP180 contains immunodominant epitopes, and
anti-NC16A IgG antibodies correlate with disease activity.7–9
Interestingly, IgE autoantibodies targeting pemphigoid antigens
were demonstrated in serum and skin of BP patients as well.8
IgE is a key mediator of allergic responses by inducing degran-
ulation of mast cells and basophils through crosslinking of IgEs
bound to high-affinity IgE receptors (FcɛRI).10 Elevated total
IgE levels in BP patients (70%) were first reported in 1974.11 Cir-
culating IgE antibodies to BP180 were observed in 30–77% of
BP patients and correlated with disease activity in several stud-
ies.8,12–18 IgE antibodies to BP230, though less extensively stud-
ied, were detected in 22–67% of BP patients.15,16,19,20 In the
skin, linear IgE deposits were reported along the basement mem-
brane zone (BMZ)21–24, whereas other reports detected IgE
bound to eosinophils and mast cells in the dermis.18,25 Recently,
Ben Mordehai et al.26 assessed total IgE levels in NBP and
reported significantly higher levels in the serum of NBP
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compared to BP patients. However, pemphigoid-specific IgE
levels and skin biopsies were not assessed.
Omalizumab, a monoclonal antibody targeting IgE, has been
used therapeutically in several BP patients.27,28 A meta-analysis
found complete responses in approximately 84% of patients,
with decreased pruritus and blister development.28 These results
imply an important role for IgE in the disease mechanism of BP,
and potentially in blister formation.
The aim of this study was to assess whether IgE is implicated
in blister formation, by comparing the presence of IgE antibod-
ies in the serum and skin of patients with NBP and BP.
Materials and methods
Selection of patients and controls
Patients diagnosed with pemphigoid at our Center for Blistering
Diseases were retrospectively selected. Patients were diagnosed
with NBP or BP if two of the following three diagnostic criteria
were met: (i) compatible clinical features of pruritus and/or
cutaneous blisters, (ii) positive linear IgG or C3c staining by
direct immunofluorescence (DIF) microscopy and (iii) positive
IgG staining on the epidermal side of salt-split skin by in DIF
microscopy.3
Sixty-eight NBP patients were included, of whom clinical,
diagnostic and prognostic features have been published sepa-
rately.5 Fifty consecutive BP patients diagnosed between 2014
and 2015 were selected retrospectively for comparison. Leftover
diagnostic material was used, consisting of serum samples taken
for immunoserology and biopsies taken for DIF microscopy,
both stored at minus 80 degrees Celsius. Patient characteristics,
and data concerning peripheral eosinophilia, and eosinophils in
lesional haematoxylin–eosin stained skin biopsies were noted if
available.
Control sera included 25 consecutive pemphigus patients with
high levels of autoantibodies to desmoglein 1 and/or 3, and 25
consecutive elderly patients with pruritus who tested negative
for pemphigoid. The study was approved by the local Ethics
Committee (University Medical Center Groningen, the Nether-
lands).
Laboratory tests
Enzyme-linked immunosorbent assay IgE antibodies against
BP180 and BP230 were measured by enzyme-linked
immunosorbent assay (ELISA) using NC16A and BP230 coated
plates from MBL (Nagoya, Japan). Optimization was performed
by testing serial dilutions of serum (1 : 25, 1 : 50, 1 : 100) and
secondary antibody (1 : 125, 1 : 250, 1 : 500). Samples were
diluted 1 : 25 with phosphate-buffered saline (PBS) with 0.05%
Tween-20 and 0.5% bovine serum albumin, and incubated for
1 h at room temperature. Anti-human IgE-horseradish peroxi-
dase (Acris, Herford, Germany) was diluted 1 : 250 and used as
conjugate with 1 h incubation time. A substrate was added for
30 min after which the enzyme reaction was stopped. Optical
density values were measured with a spectrophotometer, set to
450 nm.
IgG cross-reactivity was tested by protein G column chro-
matography, running a patients serum with high titres for anti-
NC16A IgE and IgG through a protein G column. The IgG-de-
pleted flow-through and IgG-rich fraction were both collected.
The flow-through showed a complete negative result on the IgG
ELISA and remained equally positive for IgE. Conversely, the
IgG-rich fraction was positive by IgG ELISA, and completely
negative for IgE, showing no cross-reactivity.
Previous studies with similar methodologies reported that
antigen-specific IgE antibodies in sera of BP and epidermolysis
bullosa acquisita could be effectively measured without pread-
sorption of IgG, and showed no significant difference in OD val-
ues between pre- and postadsorption of IgG.17,29
The diagnostic accuracy of the novel IgE ELISA was examined
by receiver operating characteristic curve analysis. The area
under the curve for the anti-NC16A IgE ELISA was 0.507, and
0.553 for the anti-BP230 IgE ELISA, indicating that they were
unsuitable as diagnostic tests for pemphigoid. The ELISA cut-off
values were set on the mean plus three times the standard devia-
tion of sera of the pemphigus control population (A450 0.620 for
anti-NC16A ELISA; 0.929 for anti-BP230 ELISA).
Serum total IgE was measured by Phadia immunoCap tech-
nology (cut-off value ≥115 kU/L).
Immunofluorescent IgE staining of skin biopsies Skin biopsies
taken for DIF microscopy of 14 NBP and 14 BP patients with
the highest anti-NC16A IgE titres were additionally stained for
IgE. According to our standard protocol for DIF microscopy,
biopsies were kept in saline overnight at room temperature
before storage at minus 80 degrees Celsius.
We used polyclonal rabbit anti-human IgE, ɛ-chain specific
(Dako, Glostrup, Denmark) diluted 1 : 200 with PBS contain-
ing 1% ovalbumin, and incubated for 30 min. Slides were
washed for 15 min with PBS. In a second step, polyclonal
donkey anti-rabbit IgG was used with a fluorescein isothio-
cyanate label (Jackson, Ely, UK) diluted 1 : 100 with PBS con-
taining 1% ovalbumin and incubated for 30 min. Biopsies were
washed for 15 min with PBS and viewed independently by two
authors (AL and GD). Any discrepancies between ratings were
discussed.
To study IgE staining patterns in a larger sample of control
skin, diagnostic biopsies received by our immunodermatology
laboratory of patients without an autoimmune blistering disease
were additionally stained for IgE during a period of 3 months.
Statistical analysis
Non-normally distributed data are presented as median with
interquartile range (IQR). Correlations between binary data were
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analysed by the chi-squared test, or the Fisher’s exact test when
required. The Mann–Whitney U-test was used for comparing
non-normally distributed data. A P-value < 0.05 was considered
statistically significant. Statistical analyses were performed using
IBM SPSS Statistics 23 software (IBM, Armonk, NY, USA).
Results
Patient characteristics are described in Table 1. The median age
of pemphigoid patients and elderly controls corresponded
(79 years, IQR = 14 vs. 76 years, IQR = 10).
IgE in serum
Total and specific IgE against NC16A and BP230 Total IgE
and IgE ELISA results are shown in Table 1. Pemphigoid-speci-
fic IgE autoantibodies were more commonly detected in BP
(NC16A 18%, BP230 34%) than in NBP (NC16A 9%, BP230
22%); however, no significant difference was found (P = 0.139
and P = 0.149, respectively). Overall, median IgE ELISA titres
were significantly higher in BP compared with NBP (P < 0.001).
In general, elevated total IgE was associated with specific IgE
to NC16A (P = 0.004) and BP230 (P < 0.001). In NBP, elevated
total IgE levels were associated with specific IgE to BP230
(P < 0.001) but not to NC16A (P = 0.339). Conversely, in BP a
strong association was found between elevated total IgE and
specific IgE to NC16A (P = 0.007), but not to BP230
(P = 0.058). In elderly controls with pruritus, no associations
were observed between either elevated total IgE levels or specific
IgE to NC16A or BP230 (P = 1.000 and P = 0.061).
Associations between serum IgE and IgG autoantibod-
ies Specific IgE autoantibodies to NC16A did not correlate
with IgG autoantibodies to NC16A in serum of NBP and BP
patients (P = 0.363 and P = 0.141). However, when analysing
pemphigoid as one group, we did find an association between
specific IgE and IgG autoantibodies to NC16A (P = 0.009).
Table 1 Patient characteristics and results of IgE ELISA in pemphigoid patients and controls














Median age, years (IQR) 79.0 (16) 78.0 (14) 0.794 60.0 (29) 76.0 (10)
Gender
Male, n (%) 29 (42) 15 (30) 0.160 17 (68) 12 (48)
Female, n (%) 40 (58) 35 (70) 8 (32) 13 (52)
Eosinophilia, n (%) (>0.40 109/L) 26 of 58 (44.8) 10 of 27 (37.0) 0.499 1 of 13 (7.7) 6 of 10 (60)
Lesional histopathology biopsy 37 of 54 (68.5) 18 of 20 (90.0)
Eosinophils in dermal infiltrate, n (%) 3 of 54 (5.6) 6 of 20 (30.0) 0.123
Eosinophilic spongiosis, n (%) 0.014
DIF positive for linear IgG and/or C3c along the BMZ, n (%) 40 of 67 (59.7) 44 (88.0) 0.001 0 0
IIF on SSS, positive for IgG (roof), n (%) 45 (66.2) 44 (88.0) 0.007 0 0
IgG ELISA
Positive NC16A IgG ELISA, n (%) 21 (30.9) 33 (66) <0.001 0 1 of 18 (4)
Positive BP230 IgG ELISA, n (%) 30 (46.9) 27 (54) 0.450 0 1 of 9 (4)
If positive, ELISA titre NC16A, median (IQR) 32.0 (40) 65.0 (94) 0.016 21
If positive, ELISA titre BP230, median (IQR) 29.50 (28) 51.0 (44) 0.067 15
Study results
Elevated total IgE, (≥115 kU/L) 42 (62.7) 28 (59.6) 0.737 5 (20) 15 (60)
Median total IgE (IQR), kU/L 243 (970.1) 164 (554.8) 0.350 40 (83.2) 137 (300.7)
IgE ELISA
OD value anti-NC16A IgE, median (IQR) 213.0 (120) 354.5 (225) <0.001 288 (97) 294 (70)
OD value anti-BP230 IgE, median (IQR) 402.5 (567) 559.5 (611) <0.001 475 (203) 545 (272)
Positive NC16A IgE ELISA†, n (%) 6 (8.8) 9 (18.0) 0.139 0 2 (8)
Positive BP230 IgE ELISA†, n (%) 15 (22.1) 17 (34.0) 0.149 0 5 (20)
Positive NC16A and BP230 IgE ELISA, n (%) 2 (2.9) 3 (6.0) 0.649 0 0
Bold values were statistically signifcant (p<0.05)
BMZ, basement membrane zone; DIF, direct immunofluorescent microscopy; ELISA, enzyme-linked immunosorbent assay; IIF, indirect immunofluorescent
microscopy; IQR, interquartile range; kU, kilo unit; OD, optical density; SSS, salt-split skin.
†Cut-off 620 (3xSD pemphigus). ‡Cut-off 929 (3xSD pemphigus).
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Specific IgE antibodies to BP230 were strongly associated with
IgG antibodies to BP230 in both NBP and BP patients
(P < 0.001 and P = 0.001), and in pemphigoid patients as one
group (P < 0.001).
Specific IgE autoantibodies to NC16A were not associated
with linear IgG along the BMZ by DIF in NBP and BP
(P = 1.000; P = 1.000). Specific IgE antibodies to BP230 were
associated with a negative DIF result in NBP (P = 0.013), but
not in BP (P = 0.162).
IgE in the skin
Biopsies for DIF microscopy of 14 patients of each pemphigoid
phenotype were stained for IgE. NBP biopsies were taken from
lesional (n = 6), perilesional (n = 6) and healthy skin (n = 1),
and from an unknown location in one patient. BP biopsies were
taken from perilesional (n = 9), lesional (n = 2) or healthy skin
(n = 2), and from the buccal mucosa in one patient.
IgE on the surface of cells in the dermis IgE in skin was mainly
observed on the surface of cells in the upper dermis (NBP 71%
and BP 86%; Figs 1a–c and 2a–c; Table 2). Two of 14 BP biop-
sies lacked IgE-expressing cells: one taken from buccal mucosa
and one from healthy skin. Four of 14 NBP biopsies showed no
IgE-expressing cells: three taken from perilesional skin and one
from healthy skin. The latter NBP healthy skin biopsy did, how-
ever, show linear IgE staining along the BMZ.
The presence of IgE on cells was not associated with circulat-
ing specific IgE antibodies to NC16A and BP230 (P = 0.648 and
P = 1.000). However, the cell-surface expression of IgE did cor-
relate with circulating IgG antibodies to NC16A (P = 0.038),
and with positive linear IgG staining along the BMZ (P = 0.021)
by DIF microscopy. No correlation was found with circulating
IgG antibodies to BP230 (P = 0.673).
In BP patients, median total IgE levels were significantly
higher in patients with IgE-expressing cells in the upper dermis
(659 vs. 87; P = 0.048). Such a correlation was not found in
NBP patients (P = 0.777). No significant differences in median
titres of specific IgE to NC16A and BP230 were observed in
pemphigoid patients with or without IgE-positive cells present
in the skin.
Linear IgE along the basement membrane zone In total, two
biopsies (7%, 1 NBP and 1 BP) showed IgE deposits along the
BMZ (Figs 1d and 2d; Table 2). Both biopsies with linear IgE
staining were taken from healthy skin. The NBP patient had no
specific IgE against NC16A and BP230, but showed IgG
Figure 1 Immunofluorescent staining of IgE in the skin of bullous pemphigoid (BP) patients. (a) Many IgE-positive cells in the dermis
(++), representative for five of 14 BP skin samples. (b) Multiple IgE-positive cells in the dermis (+), representative for one of 14 BP skin
samples. (c) Few IgE-positive cells in the dermis (+/), representative for six of 14 BP skin samples. (d) One BP skin sample showed linear
IgE along the basement membrane zone, while 13 other skin samples did not. White bar is 50 lm.
© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology
JEADV 2020
4 Lamberts et al.
antibodies to NC16A. The BP patient was positive for IgE and
IgG antibodies to BP230, but not to NC16A. Both patients had
linear IgG along the BMZ by DIF microscopy.
Additional IgE staining of diagnostic skin biopsies In total, 122
biopsies of subjects suspected of autoimmune blistering diseases,
but with negative routine IgG diagnostic pemphigoid tests, were
stained for IgE. None of the biopsies showed IgE in a linear
pattern along the BMZ. Binding of IgE on a few cells was seen
occasionally, but less frequently and extensively as in either BP
or NBP biopsies.
Eosinophils and IgE in serum and histopathologic skin
biopsies
Data on eosinophils in serum and lesional histopathologic skin
biopsies of pemphigoid patients are shown in Table 1.
Peripheral eosinophilia was significantly associated with ele-
vated total IgE levels in NBP (P = 0.028), but not in BP
(P = 0.208). No associations were found between peripheral
eosinophilia and specific IgE antibodies to NC16A and BP230
(P = 0.516 and P = 0.326). Peripheral eosinophilia was also not
associated with IgE on cells (P = 0.594), or IgE in a linear pat-
tern along the BMZ (P = 0.481).
No correlations were found between the presence of eosino-
phils in histopathologic lesional skin biopsies, and results of total
IgE, specific IgE to NC16A/BP230, IgE in the skin on cells in the
upper dermis, or IgE in the skin in a linear pattern along the
BMZ (data not shown).
Discussion
IgE autoantibodies were clearly present in the serum and skin of
both NBP and BP patients. Although not statistically significant,
circulating specific IgE to NC16A and BP230 was more often
Figure 2 Immunofluorescent staining of IgE in the skin of non-bullous pemphigoid (NBP) patients. (a) Many IgE-positive cells in the der-
mis (++), representative for two of 14 NBP skin samples. (b) Multiple IgE-positive cells in the dermis (+), representative for four of 14 NBP
skin samples. (c) Few IgE-positive cells in the dermis (+/), representative for four of 14 NBP skin samples. (d) One BP skin sample
showed linear IgE along the basement membrane zone, while 13 other skin samples did not. White bar is 50 lm.







n (%) n (%)
IgE deposits linear along the BMZ 1 (7.1) 1 (7.1)
Positive, ++ 0 (0) 1 (7.1)
Positive, + 1 (7.1) 0 (0)
Negative 12 (85.7) 12 (85.7)
IgE on cells in the dermis 10 (71.4) 12 (85.7)
Positive, ++ many cells 2 (14.3) 5 (35.7)
Positive, + multiple cells 4 (28.6) 1 (7.1)
Positive, +/ only few cells 4 (28.6) 6 (42.9)
Negative 4 (28.6) 2 (14.3)
BMZ, basement membrane zone.
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detected in BP (18% and 34%) than in NBP (9% and 22%). In
the skin, IgE was most frequently observed on dermal cells (NBP
71% and BP 86%), and only two biopsies (7%; 1 NBP, 1 BP)
showed linear IgE depositions along the BMZ. These findings
imply that IgE autoantibodies could have indirect effects on blis-
tering by binding to immune cells, likely eosinophils and mast
cells, but other factors presumably play a more conclusive role
in whether pemphigoid patients form blisters or not.
In contrast with the findings of Ben Mordehai et al., our study
did not detect significantly higher total IgE levels in NBP com-
pared with BP serum.26 Overall, pemphigoid-specific IgE was
more frequently directed to BP230 than to NC16A, in line with
several BP studies.15,30 Predominant reactivity of IgE to intracel-
lular BP230 might account for the low occurrence of linear IgE
staining by DIF. Hashimoto et al.17 reported an association
between specific IgE to BP230 and a pemphigoid nodularis phe-
notype. Interestingly, subanalysis of previously published clinical
NBP data5 showed a similar trend, with 47% of the NBP patients
with specific IgE to BP230 presenting with papules and nodules
(P = 0.121; data not shown). This suggests that specific IgE to
BP230 might be pathognomonic for a prurigo nodularis-like
pemphigoid phenotype. In NBP, specific IgE to NC16A or
BP230 was not associated with an urticarial phenotype, similar
to previous reports on BP.13,17,31
Overall, we found a lower percentage of IgE reactivity to
NC16A and BP230 by ELISA in BP patients, compared with
other studies.8,12–20 This might be dependent on methodological
differences of established IgE assays, such as serum dilutions, or
determined cut-off values. Another explanation could be differ-
ences between the BP study cohorts, since the percentage of IgG
reactivity to BP180 and BP230 in our consecutive BP patients
was lower (66% and 44%, respectively) compared with other
studies (90% and 60%, respectively) that might have selected
their patients differently.32
We observed linear IgE along the BMZ in only two of 24 pem-
phigoid biopsies (7%), while others reported linear IgE in 0%,
3%, 18%, 25% and 44% of BP biopsies, indicating that linear
IgE is not commonly observed in pemphigoid skin.18,21–25 Dif-
ferences in methodology and biopsy location may account for
the discrepancies between these studies.
Interestingly, IgE on the surface of dermal cells was associated
with IgG reactivity to NC16A (82%; P = 0.038), and linear IgG
deposits along the BMZ by DIF (86%; P = 0.021), but not with
pemphigoid-specific IgE. Our study did not specify the cell types
expressing IgE. However, previous studies identified IgE on mast
cells and eosinophils in perilesional BP skin.18,25 It has been
hypothesized that IgE could induce mast cell and eosinophil
degranulation, releasing proteolytic enzymes matrix metallopro-
tease-9 and neutrophil elastase, substances that are known to
cleave the extracellular domain of BP180 in vitro.33–35 This has
recently been supported by a murine BP model demonstrating
eosinophil-dependent blister formation following sensitization
with NC16A-specific IgE.36 Furthermore, since omalizumab
(anti-IgE) therapy reduces both pruritus and blisters, a role for
IgE in blister formation is supported.28 In contrast, our data do
not support the hypothesis that IgE plays an essential role in
blister formation in pemphigoid, since we observed IgE on cells
in the dermis in 71% of NBP patients that clinically lack blisters.
Based on our findings, it is likely that factors other than IgE
are more important for blister development. Several studies des-
ignate eosinophils as the most important regulators of blister
formation, since activated eosinophils were shown to accumulate
in serum, skin and blister fluids of BP, and were able to induce
dermal–epidermal separation upon activation by IL-5.37–39
Beside FcɛRI, eosinophils also express receptors for complement
anaphylatoxins C3a and C5a.40–42 These complement anaphyla-
toxins not only orchestrate eosinophil migration, but were also
capable to evoke eosinophil degranulation.42 Previous studies
demonstrated that complement activation might be important
for blister formation in BP.43–45 Nonetheless, others found evi-
dence for blister induction via complement-independent path-
ways by IgG and IgE antibody induced internalization of the
complete BP180 molecule.46–49
Surprisingly, a subset of elderly controls with pruritus showed
specific IgE antibodies to NC16A and BP230 in the absence of
IgG autoantibodies to these antigens. In contrast, none of the
pemphigus controls had pemphigoid-specific IgE. In accordance,
Freire et al.25 reported specific IgE antibodies to BP180 in one-
third of healthy control sera. Previously, IgG autoantibodies to
NC16A and BP230 by ELISA were detected in elderly individu-
als, chronic pruritus patients, healthy controls and dermatology
patients, all without pemphigoid.50–54 It has been suggested that
repeated cell injury, for example by scratching, could expose
new and otherwise hidden antigens to the immune system, a
phenomenon termed epitope spreading.55 Moreover, ageing of
the immune system can result in a pro-inflammatory immune
status, increasing the risk of autoimmunity.56 Both events could
conceivably contribute to the development of IgE and IgG
autoantibodies in elderly controls with pruritus. Yet, the rele-
vance of these autoantibodies in individuals without pem-
phigoid remains unknown. Neurodegenerative diseases, such as
multiple sclerosis and Parkinson’s disease, may precede BP, and
the expression of BP180 and BP230 in both skin and brain tissue
suggests that cross-reactivity could initiate BP.57 However, fur-
ther research is necessary to demonstrate whether BP should be
seen as a neuro-cutaneous disease rather than a skin disease.
This study has several limitations, of which the most impor-
tant is its retrospective nature. Consequently, diagnostic skin
samples were taken from different locations by different health-
care professionals. Moreover, our study only assessed IgE target-
ing NC16A; therefore, no conclusions could be drawn on IgE
antibodies to other BP180 epitopes. Previous epitope mapping
studies of BP180 IgE in BP sera mainly detected NC16A reactiv-
ity; however, reactivity to other extracellular and intracellular
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domains of BP180 has been reported.25,58,59 No epitope mapping
data of NBP are available.
In conclusion, IgE in NBP and BP skin was more often found
on the surface of immune cells rather than deposited linear
along the BMZ. The IgE ELISAs for NC16A and BP230 were
slightly more often positive in BP than in NBP patients, how-
ever, are unsuitable as a diagnostic pemphigoid test due to low
specificity. Our main finding is that IgE autoantibodies are pre-
sent in serum and skin of both NBP and BP patients, supporting
the notion that IgE potentially modulates pruritus associated
with these pemphigoid diseases rather than being centrally
involved in blister formation per se. Further studies, however,
are needed to determine why blisters are absent in NBP, and to
understand the exact role of IgE in the disease mechanism of
pemphigoid.
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